SERDEChNO-SOSUDISTYE ZABOLEVANIYa I OSTEOPOROZ


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

In recent years, the relationship of cardiovascular disease (CVD) and osteoporosis is actively discussing in the scientific literature and the medical community. The results of a number of epidemiological studies that found an associative relationship between vascular calcification and bone health were the basis for the discussion. The article discusses risk factors and pathogenesis of bone diseases and cardiovascular diseases. Rational algorithm for the management of patients with cardiovascular diseases and skeletal system disorders is presented. Particular attention is paid to the preparation Alphadol-Ca, 1 capsule of which contains 0.25 micrograms of vitamin D predecessor analogue alphacalcidol and 200 mg of calcium carbonate. It was found that vitamin D analogues, such as alfacalcidol, have a positive effect on bone remodeling and bone microarchitectonics; moreover, such drugs have a particular advantages as proven immunomodulatory and anticytokine effects, that justifies their use by persons with concomitant pathology of cardiovascular and bone systems.

Full Text

Restricted Access

References

  1. Warburton DE, Nicol CW, Bredin SS. Health benefits of physical activity: the evidence. Cmaj 2006;174:801-09.
  2. Schulz E, Arfai K, Liu X, et al. Aortic calcification and the risk of osteoporosis and fractures. J Clin Endocrinol Metab 2004;89:4246-53.
  3. World Health Organization. World Health Organization 2006.
  4. Katzmarzyk PT, Gledhill N, Shephard RJ. The economic burden of physical inactivity in Canada. Cmaj. 2000;163:1435-40.
  5. Public Health Agency of Canada. Ottawa, Ontario: Public Health Agency of Canada 2002; 102.
  6. Osteoporosis Canada. Osteoporosis Canada, Toronto, Ontario 2007.
  7. National Osteoporosis Foundation. Washington, DC: National Institute of Health 2007.
  8. Brown JP, Josse RG. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. Cmaj 2002;167:S1-34.
  9. Statistics Canada. Ottawa, Ontario: Statistics Canada 1999.
  10. Heinrich J, Assmann G. Fibrinogen and cardiovascular risk. J Cardiovasc Risk 1995;2: 197-205.
  11. Grey E, Bratteli C, Glasser SP, et al. Reduced small artery but not large artery elasticity is an independent risk marker for cardiovascular events. Am J Hypertens 2003; 16:265-69.
  12. McKay H, JPC, Ahamed Y, et al. BC Ministry of Health Services Victoria, BC 2004.
  13. Canadian Multicentre Osteoporosis Study. Canadian Multicentre Osteoporosis Study 2006.
  14. Bagger YZ, Tanko LB, Alexandersen P, et al. Radiographic measure of aorta calcification is a site-specific predictor of bone loss and fracture risk at the hip. J Intern Med 2006; 259:598-605.
  15. Barengolts EI, Berman M, Kukreja SC, et al. Osteoporosis and coronary atherosclerosis in asymptomatic postmenopausal women. Calcif Tissue Int 1998;62:209-13.
  16. Yamaguchi T, Sugimoto T, Yano S, et al. Plasma lipids and osteoporosis in postmenopausal women. Endocr J 2002;49:211-17.
  17. Uyama O, Yoshimoto Y, Yamamoto Y, et al. Bone changes and carotid atherosclerosis in postmenopausal women. Stroke 1997; 28:1730-32.
  18. Schwartz AV, Sellmeyer DE, Strotmeyer ES, et al. Diabetes and bone loss at the hip in older black and white adults. J Bone Miner Res 2005;20:596-603.
  19. Laroche M, Moulinier L, Leger P, et al. Bone mineral decrease in the leg with unilateral chronic occlusive arterial disease. Clin Exp Rheumatol 2003;21:103-06.
  20. Bocchi L, Orso CA, Passarello F, et al. Atherosclerosis of the vessels in the ligamentum teres. Optical and electron microscopy findings in elderly patients with femoral neck fractures. Ital J Orthop Traumatol 1987;13:365-69.
  21. Vogt MT, Cauley JA, Kuller LH, et al. Bone mineral density and blood flow to the lower extremities: the study of osteoporotic fractures. J Bone Miner Res 1997;12:283-89.
  22. Kado DM, Browner WS, Blackwell T, et al. Rate of bone loss is associated with mortality in older women: a prospective study. J Bone Miner Res 2000;15:1974-80.
  23. Tanko LB, Christiansen C, Cox DA, et al. Relationship between osteoporosis and cardiovascular disease in postmenopausal women. J Bone Miner Res 2005;20:1912-20.
  24. Sinnott B, Syed I, Sevrukov A, et al. Coronary calcification and osteoporosis in men and postmenopausal women are independent processes associated with aging. Calcif Tissue Int 2006;78:195-202.
  25. Doherty TM, Asotra K, Fitzpatrick LA, et al. Calcification in atherosclerosis: bone biology and chronic inflammation at the arterial crossroads. Proc Natl Acad Sci USA 2003; 100:11201-6.
  26. Rubin MR, Silverberg SJ. Vascular calcification and osteoporosis - the nature of the nexus. J Clin Endocrinol Metab 2004;89:4243-45.
  27. Blake GJ, Ridker PM. Novel clinical markers of vascular wall inflammation. Circ Res 2001; 89:763- 71.
  28. Rossouw JE. Coronary heart disease in menopausal women: implications of primary and secondary prevention trials of hormones. Maturitas 2005;51:51-63.
  29. Baldini V, Mastropasqua M, Francucci CM, et al. Cardiovascular disease and osteoporosis. J Endocrinol Invest 2005;28:69-72.
  30. Rajzbaum G, Bezie Y. Postmenopausal osteoporosis and atheroma. Joint Bone Spine 2006;73:661-66.
  31. Yano K, Tsuda E, Washida N, et al. Immunological characterization of circulating osteoprotegerin/ osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis. J Bone Miner Res 1999;14:518-27.
  32. Browner WS, Lui LY, Cummings SR. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab 2001; 86:631-37.
  33. Kiechl S, Schett G, Wenning G, et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 2004;109:2175-80.
  34. Parhami F, Basseri B, Hwang J, et al. High-density lipoprotein regulates calcification of vascular cells. Circ Res 2002;91:570-76.
  35. Bagger YZ, Rasmussen HB, Alexandersen P, et al. Links between cardiovascular disease and osteoporosis in postmenopausal women: serum lipids or atherosclerosis per se. Osteoporos Int 2007;18:505-12.
  36. Adami S, Braga V, Zamboni M, et al. Relationship between lipids and bone mass in 2 cohorts of healthy women and men. Calcif Tissue Int 2004;74:136-42.
  37. Whitney C, Warburton DE, Frohlich J, et al. Are cardiovascular disease and osteoporosis directly linked. Sports Med 2004;34:779-807.
  38. Armour KE, Armour KJ, Gallagher ME, et al. Defective bone formation and anabolic response to exogenous estrogen in mice with targeted disruption of endothelial nitric oxide synthase. Endocrinology 2001;142:760-66.
  39. Fiore CE, Pennisi P, Cutuli VM, et al. L-arginine prevents bone loss and bone collagen breakdown in cyclosporin A-treated rats. Eur J Pharmacol 2000;408:323-26.
  40. Nabhan AF. A randomized clinical trial of the effects of isosorbide mononitrate on bone formation and resorption in post-menopausal women: a pilot study. Hum Reprod 2006;21: 1320-24.
  41. Judd S.E., Tangpricha V. Vitamin D Deficiency and Risk for Cardiovascular Disease. Am J Med Sci 2009, 338(1): 40-4.
  42. Kendrick J, Targher G, Smits G. et al. 25-Hydroxyvitamin D deficiency is independently associated with cardiovascular disease in the Third National Health and Nutrition Examination Survey. Atherosclerosis 2009;205(1):255-60.
  43. Kim DH, Sabour S, Sagar UN, et al. Prevalence of hypovitaminosis D in cardiovascular diseases (from the National Health and Nutrition Examination Survey 2001 to 2004). Am J Cardiol 2008;102:1540-44.
  44. Martins D, Wolf M, Pan D, et al. Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States: data from the Third National Health and Nutrition Examination Survey. Arch Intern Med 2007;167:1159-65.
  45. Scragg R, Sowers M, Bell C. Serum 25-hydroxyvi-tamin D, ethnicity, and blood pressure in the Third National Health and Nutrition Examination Survey. Am J Hypertens 2007;20:713-19.
  46. Melamed ML, Muntner P, Michos ED, et al. Serum 25-hydroxyvitamin D levels and the prevalence of peripheral arterial disease: results from NHANES 2001 to 2004. Arterioscler Thromb Vasc Biol 2008;28:1179-85.
  47. Wang TJ, Pencina MJ, Booth SL, et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008; 117:503-11.
  48. Zittermann A, Schleithoff SS, Koerfer R. Vitamin D and vascular calcification. Curr Opin Lipidol 2007;18:41-6.
  49. Fitzpatrick LA, Bilezikian JP, Silverberg SJ. Parathyroid hormone and the cardiovascular system. Curr Osteoporos Rep 2008;6:77-83.
  50. Lacroix AZ, Kotchen J, Anderson G, et al. Calcium plus vitamin D supplementation and mortality in postmenopausal women: the Women's Health Initiative calcium-vitamin D randomized controlled trial. J Gerontol A Biol Sci Med Sci 2009; 64:559-67.
  51. Trivedi DP, Doll R, Khaw KT. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomized double blind controlled trial. BMJ 2003;326:469.
  52. Vieth R, Bischoff-Ferrari H, Boucher BJ, et al. The urgent need to recommend an intake of vitamin D that is effective. Am J Clin Nutr 2007; 85:649-50.
  53. Rosen C.J. Vitamin D Insufficiency. N Engl J Med 2011 ;364:248-54.
  54. Tang BM, Eslick GD, Nowson C, Smith C, Bensoussan A. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet 2007;370: 657-66.
  55. Avenell A, Gillespie WJ, Gillespie LD, O'Connell D. Vitamin D and vitamin D analogues for preventing fractures associated with involutional and postmenopausal osteoporosis. Cochrane Database Syst Rev 2009;2:CD000227.
  56. Chung M, Balk E, Brendel M, et al. Vitamin D and calcium: a systematic review of health outcomes. Evidence report/technology assessment no. 183. Rockville, MD: Agency for Healthcare Research and Quality 2009.
  57. Bischoff-Ferrari HA, Dawson-HughesB, Willett WC, et al. Effect of vitamin D on falls: a meta-analysis. JAMA 2004;291:1999-2006.
  58. Jackson RD, LaCroix AZ, Gass M, et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 2006;354:669-83.
  59. Bunout D, Barrera G, Leiva L, et al. Effects of vitamin D supplementation and exercise training on physical performance in Chilean vitamin D deficient elderly subjects. Exp Gerontol 2006;41:746-52.
  60. Salovaara K, Tuppurainen M, Karkkainen M, et al. Effect of vitamin D3 and calcium on fracture risk in 65- to 71-year old women: a population based 3-year randomized controlled trial - the OSTPREFPS. J Bone Miner Res 2010;25:1487-95.
  61. Wang L, Manson JE, Sesso HD. Calcium intake and risk of cardiovascular disease: a review of prospective studies and randomized clinical trials. Am J Cardiovasc Drugs 2012 1;12(2):105-16.
  62. Bolland MJ, Grey A, Avenell A, Gamble GD, Reid IR. Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-analysis. BMJ 2011; 342:d2040.
  63. Zitterman A, Pilz S, Borgermann J, Gummert JF. Calcium supplementation and vitamin D: a trigger for adverse cardiovascular events? Future Cardiol 2011;7(6):725-27.
  64. Rachner TD, Khosla S, Hofbauer LC. Osteoporosis: now and the future. Lancet 2011;3 77(9773):12 76-87.
  65. Winzenberg T, van der Mei I, Mason RS, Nowson C, Jones G. Vitamin D and the musculoskeletal health of older adults. Aust Fam Physician 2012;41(3):92-9.
  66. Warburton D, Nicol CW, Gatto SN, Bredin S. Cardiovascular disease and osteoporosis: balancing risk management. Vascular health and risk management 2007;3(5):673-89.
  67. Никитинская О.А., Торопцова Н.В. Кальций и витамин D: анализ возможных положительных и отрицательных побочных явлений при их применении//РМЖ 2011. № 10. С. 651-55.
  68. Schacht E, Richy F, Reginster JY. The therapeutic effects of alfacalcidol on bone strength, muscle metabolism and prevention of falls and fractures. J. Musculoskelet Neuronal Interact 2005; 5(3):273-84.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies